Diagnostic markers and drug targets for Parkinson's disease

A Parkinson's disease and biomarker technology, applied in the field of biomedicine, can solve the problem that the pathogenesis of PD is not fully understood

Inactive Publication Date: 2020-03-24
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, the etiology and exact pathogenesis of PD are still not completely clear. The in vivo and in vitro experiments of most scholars have confirmed that pathways such as mitochondrial dysfunction, oxidative stress, and ubiquitinated proteasome a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnostic markers and drug targets for Parkinson's disease
  • Diagnostic markers and drug targets for Parkinson's disease
  • Diagnostic markers and drug targets for Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Example 1 Study on the correlation between ELL gene expression and Parkinson's disease diagnosis

[0060] 1. Research object

[0061] A total of 55 patients with primary PD were collected, including 30 males and 25 females, aged 34-80 years old, with a course of 6 months-20 years. PD inclusion criteria: the diagnostic criteria are in line with the clinical diagnostic criteria of PD (refer to "Jiang Yuping, Wang Jian, Ding Zhengtong, etc., Diagnostic Criteria for Primary Parkinson's Disease, 2005, Chinese Clinical Neuroscience, 2006, 14:40" ). Exclusion criteria: (1) essential tremor; (2) secondary Parkinson's syndrome; (3) severe dementia and dysarthria; (4) patients with other mental illnesses.

[0062] Normal group: 40 healthy volunteers aged 34-80 years old, 20 men and women each.

[0063] There was no statistically significant difference in age and gender between the two groups (P> 0.10), comparable.

[0064] 2. Extraction of total RNA from blood

[0065] (1) Homogenization...

Embodiment 2

[0099] Example 2 Inhibition of ELL gene expression

[0100] 1. Cell culture

[0101] Culture SH-SY5Y cells in an incubator. The culture medium is DMEM high glucose culture medium (GIBCO) containing 100U / ml penicillin, 100μg / ml streptomycin and 10% fetal bovine serum. The culture conditions are set to 37℃, 5% CO2 . Separate the cells from the bottle wall, use 25% trypsin to separate the cells, and pass them at a ratio of 1:2-1:3. After three passages, select the cells in good condition and freeze them, and perform the experiment when other passaged cells enter the logarithmic growth phase.

[0102] 2. Design and synthesize siRNA against ELL

[0103] According to the ELL mRNA sequence, online siRNA design software (http: / / www.ambion.com) is used. According to the design principles provided by Ambion, a pair of siRNA sequences specifically targeting the ELL gene was screened out. The siRNA sequence was synthesized by Guangzhou Ruibo Biotechnology Co., Ltd. The above sequence was ver...

Embodiment 3

[0113] Example 3 Study on the correlation between ELL gene expression and the treatment of Parkinson's disease

[0114] 1. Preparation of MPP+

[0115] Dissolve 10 mg of MPP+ (sigma) in 1 ml of cell culture medium to prepare a stock solution. Take 0.1ml of the stock solution and add it to the cell culture solution. The cell culture solution is 0.9ml to prepare a 3365.5μM MPP+ working solution.

[0116] 2. Construction of Parkinson's disease cell model

[0117] Preliminary experiments have proved that using 4mM MPP+ administration concentration can induce damage to SH-SY5Y cells for 24h, and the cell survival rate is about 60%. Therefore, 4mM MPP+ can establish a stable Parkinson's disease cell model.

[0118] 3. The effect of interference with ELL gene expression on SH-SY5Y cell damage induced by MPP+

[0119] By measuring cell survival rate and apoptosis rate to study the effect of interference with ELL gene expression on MPP+-induced SH-SY5Y cell damage.

[0120] 3.1 MTT experiment

[0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a diagnostic marker and a drug target for Parkinson's disease, wherein the diagnostic marker and the drug target are ELL. By extracting the peripheral blood of a subject to detect the expression level of the ELL in monocytes, whether the subject suffers from Parkinson's disease or whether the subject has the high risk of suffering from Parkinson's disease can be judged. Theresearch results of the invention can be diagnosed in the early stage of Parkinson's disease, and drugs for treating Parkinson's disease can be developed according to the therapeutic function of reagents for inhibiting ELL expression. The invention has good market application prospects.

Description

Technical field [0001] The invention belongs to the field of biomedicine and relates to diagnostic markers and drug targets of Parkinson's disease. Background technique [0002] Parkinsoni’s disease (PD) is a degenerative disease of the nervous system that occurs in middle-aged and elderly people, and it is also the most common extrapyramidal disease in middle-aged and elderly people. Its incidence ranks second in the middle-aged and elderly population, second only to Alzheimer's disease (Alzheimefis disease, AD), and has an increasing trend year by year. With the increase in age, the incidence of men is much higher than that of women. The common clinical manifestations of PD are static tremor, delayed response, stiffness and postural distortion. Its pathological characteristics are mostly manifested as progressive, extensive degeneration and loss of dopaminergic neurons in the substantia nigra compact area, which in turn reduces the level of dopamine in the striatum, and Lewy b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6883G01N33/68A61K45/00A61P25/16
CPCA61K45/00A61P25/16C12Q1/6883C12Q2600/158G01N33/6896G01N2800/2835
Inventor 杨承刚张冬梅王麟
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap